2-amino-5-isopropyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine | 17899-51-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-amino-5-isopropyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine
• 英文别名: 5-isopropyl-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridin-2-ylamine；5-Isopropyl-4,5,6,7-tetrahydro-thiazolo[5,4-c]-pyridin-2-ylamine；5-propan-2-yl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-amine
• CAS: 17899-51-3
• 化学式: C₉H₁₅N₃S
• mdl: MFCD02854750
• 分子量: 197.304
• InChiKey: BXIPZMYZBYKUBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  331.6±32.0 °C(Predicted)
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  70.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  cis-4-(6-amino-2-chloro-9H-purin-9-yl)cyclohexanecarboxylic acid 、 2-amino-5-isopropyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 以19%的产率得到cis-4-(6-amino-2-chloro-9H-purin-9-yl)-N-[5-(propan-2-yl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]cyclohexanecarboxamide
  参考文献：
  名称：

  Identification of unprecedented ATP-competitive choline kinase inhibitors

  摘要：

  DOI：

  10.1016/j.bmcl.2021.128310
• 作为产物：
  描述：

  1-异丙基-4-哌啶酮 、 氰胺 在 四氢吡咯 、 sulfur 作用下， 以 异丙醇 为溶剂， 反应 8.0h， 以39%的产率得到2-amino-5-isopropyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine
  参考文献：
  名称：

  Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

  摘要：

  Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected beta-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.07.051

文献信息

• Hepatitis B capsid assembly modulators
  申请人：VenatoRx Pharmaceuticals, Inc.

  公开号：US11247965B2

  公开（公告）日：2022-02-15

  Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

  本文描述的是乙型肝炎囊壳组装调节剂和包含所述化合物的药物组合物。所述化合物和组合物可用于治疗乙型肝炎。
• [EN] N-SUBSTITUTED-3,5-DISUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF<br/>[FR] COMPOSÉ BENZAMIDE N-SUBSTITUÉ-3,5-DISUBSTITUÉ ET SES PROCÉDÉ DE PRÉPARATION ET APPLICATION<br/>[ZH] N-取代-3,5-二取代苯甲酰胺类化合物及其制备方法和应用
  申请人：SHANGHAI INST MATERIA MEDICA

  公开号：WO2016112863A1

  公开（公告）日：2016-07-21

  本发明公开一种N-取代-3,5-二取代苯甲酰胺类化合物及其制备方法和应用，该化合物结构如通式I所示，式中，m、X、Y、R1、R2和R3如权利要求书和说明书所示。本发明还公开了包含通式I所示化合的药物组合物。本发明的化合物可以作为葡萄糖激酶激动剂，用于预防和/或治疗与葡萄糖代谢异常相关的疾病。
• HEPATITIS B CAPSID ASSEMBLY MODULATORS
  申请人：VenatoRx Pharmaceuticals, Inc.

  公开号：US20210171439A1

  公开（公告）日：2021-06-10

  Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.